Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab vs Infliximab in Pediatric Ulcerative Colitis
NCT06614387Phase 3Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Apr 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in ulcerative colitis (UC) (2 arms). Primary endpoint: Number of drug-related adverse events at 20 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06614387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614387.